Folate metabolism in tumor-associated macrophages drives immunosuppressive function to promote tumor growth
This study reveals that tumor-associated macrophages rely on the folate receptor FRβ to maintain immunosuppressive functions in low-folate tumor environments, and that disrupting this metabolic pathway induces mitochondrial ROS-mediated cGAS-STING signaling, repolarizing macrophages toward a pro-inflammatory state that enhances anti-tumor immunity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the human body, the immune system acts as a constant patrol, seeking out and destroying abnormal cells before they can grow into dangerous tumors. Among the many soldiers in this army are macrophages, a type of white blood cell that normally cleans up debris and fights infection. However, in the environment surrounding a tumor, these cells often change their behavior. Instead of attacking the cancer, they are tricked into helping it grow, shielding the tumor from the immune system's other weapons and making standard treatments less effective. For decades, scientists have struggled to find a way to turn these helpful-but-harmful cells back into allies without harming the rest of the body. The key to this puzzle may lie in a simple nutrient: folate, a form of vitamin B that cells need to function.
A team of researchers at the University of North Carolina has discovered that tumor-associated macrophages rely on a specific, high-sensitivity tool to grab folate from their surroundings, and this dependency is what keeps them in their cancer-supporting mode. In healthy tissue, folate is plentiful, but inside a tumor, it is scarce. The researchers found that these immune cells express a unique receptor, a protein on their surface that acts like a specialized hook, allowing them to snatch up the limited folate available. When the scientists removed this hook from macrophages in mice, the cells could no longer survive well in the low-folate tumor environment. Instead of helping the cancer, they shifted their behavior, becoming aggressive fighters that recruited other immune cells to attack the tumor.
The study began by looking at human melanoma, a serious form of skin cancer. The researchers examined tumor samples from patients and found that the macrophages living inside the tumors were indeed using this special hook to gather folate. They also noticed a clear pattern: patients whose tumors were packed with these folate-grabbing macrophages tended to have worse outcomes and were less likely to respond to modern immunotherapy drugs. This suggested that the presence of these cells was a sign of a tumor that was successfully hiding from the immune system. To understand why this was happening, the team created a new line of mice that lacked the gene for this specific receptor. When they grew melanoma tumors in these mice, the tumors grew much more slowly than in normal mice.
The reason for this slowdown was a dramatic shift in the immune landscape. Without the ability to grab folate efficiently, the macrophages inside the tumor could not maintain their quiet, supportive state. They became agitated and pro-inflammatory, essentially sounding an alarm that drew in cytotoxic T cells and natural killer cells, the immune system's primary assassins. These attacking cells swarmed the tumor and began destroying the cancer cells. The researchers confirmed that this effect was driven by the immune system, as the tumors grew just as fast in the modified mice when the T cells were removed. This proved that the change in the macrophages was the trigger that unleashed the rest of the immune army.
To understand the mechanism behind this switch, the team looked closely at the chemistry inside the cells. They discovered that the tumor environment is naturally low in folate, measuring concentrations that were one hundred times lower than what is found in standard laboratory growth media. In this nutrient-poor setting, the specialized hook was essential for the macrophages to get enough folate to function. When the hook was missing, the cells became starved of this vitamin. This starvation disrupted a critical metabolic process inside the cell's power plants, the mitochondria. Without enough folate, the mitochondria began to malfunction and produce excessive amounts of reactive oxygen species, which are unstable molecules that can damage cells.
This buildup of unstable molecules caused the mitochondria to leak their internal DNA into the main part of the cell. The cell interpreted this leaked DNA as a sign of a viral infection or severe damage, triggering a powerful alarm system known as the cGAS-STING pathway. This alarm forced the macrophage to change its identity from a tumor-helper to a tumor-attacker. The researchers tested this theory by adding antioxidants to the cells, which neutralized the unstable molecules. When they did this, the macrophages increased their expression of immunosuppressive markers and decreased the production of inflammatory cytokines, effectively reversing the pro-inflammatory switch and restoring their ability to suppress T cell activity. They also showed that if they fed the mice a diet extremely high in folate, the modified mice lost their ability to control the tumors, proving that the effect was entirely dependent on the lack of this specific vitamin.
The findings offer a new perspective on how to fight cancer. Rather than trying to deplete these immune cells, which has proven difficult and toxic, the research suggests that targeting their ability to grab folate could be a powerful strategy. By blocking this specific receptor, doctors might be able to force the tumor's own defenders to turn against the cancer. The study also showed that this approach worked well in combination with existing immunotherapy drugs, suggesting that combining a folate-blocking strategy with current treatments could help more patients respond to therapy. The work highlights how a basic metabolic need, the requirement for a single vitamin, can dictate whether an immune cell saves a patient or helps a tumor survive.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.